Simultaneous co-assembly of fenofibrate and ketoprofen peptide for the dual-targeted treatment of nonalcoholic fatty liver disease (NAFLD)

Chem Commun (Camb). 2020 May 4;56(36):4922-4925. doi: 10.1039/d0cc00513d. Epub 2020 Apr 2.

Abstract

We have developed a co-assembled nanosystem based on fenofibrate and ketoprofen by tactfully utilizing their simultaneous benzophenone interaction, which greatly enhances the bioavailability of fenofibrate and plays a role in the dual-targeted treatment of NAFLD by reducing hepatic lipid accumulation and inflammatory responses.

MeSH terms

  • Fenofibrate / chemistry
  • Fenofibrate / pharmacology*
  • Humans
  • Inflammation / drug therapy*
  • Inflammation / metabolism
  • Ketoprofen / chemistry
  • Ketoprofen / pharmacology*
  • Lipid Metabolism / drug effects
  • Molecular Structure
  • Non-alcoholic Fatty Liver Disease / drug therapy*
  • Non-alcoholic Fatty Liver Disease / metabolism
  • Peptides / chemical synthesis
  • Peptides / chemistry
  • Peptides / pharmacology*

Substances

  • Peptides
  • Ketoprofen
  • Fenofibrate